On November 1, 2012, Tsuhako, Amy Lew; Marlowe, Charles K.; Zaharia, Christiana A.; Kabigting, Lori; Bajjalieh, William; Tesfai, Zerom; Huang, Ping; Moon, Kim; Aay, Naing; Tambo-Ong, Arlyn; Nuss, John M.; Xu, Wei; Kearney, Patrick published a patent.Safety of (2-Bromo-5-methoxyphenyl)methanamine The title of the patent was Pyrimidine derivatives as inhibitors of inducible form of 6-phosphofructose-2-kinase and their preparation and use for the treatment of cancer. And the patent contained the following:
The invention relates to pyrimidines of formula I, which are inhibitors of inducible form of 6-phosphofructose-2-kinase (iPFK-2) and which are useful in the treatment of cancer. Compounds of formula I wherein W is (un)substituted (un)branched C1-12 aliphatic chain; X1, X2 and X3 are independently absent, (un)substituted aryl, (un)substituted heteroaryl, etc.; Y is absent and (un)substituted (un)branched C1-12 aliphatic chain; Z is H, (un)substituted C1-8 aliphatic, (un)substituted aryl, etc.; L is absent, NH and derivatives and (un)substituted (un)branched C1-4 aliphatic chain; A is (un)substituted aryl, (un)substituted heteroaryl, etc.; and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a general procedure (procedure given). All the invention compounds were evaluated for their iPFK-2 inhibitory activity. From the assay, it was determined that compound II exhibited an IC50 value of <500 nM. The experimental process involved the reaction of (2-Bromo-5-methoxyphenyl)methanamine(cas: 887581-09-1).Safety of (2-Bromo-5-methoxyphenyl)methanamine
The Article related to pyrimidine preparation phosphofructose kinase inhibitor treatment cancer, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Safety of (2-Bromo-5-methoxyphenyl)methanamine
Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem